Biocon Biologics (BBL), a subsidiary of Biocon, announced today that Shreehas Tambe, Deputy CEO of Biocon Biologics, has been appointed as the Managing Director and CEO of the Company from 05 December 2022. Tambe will lead BBL in realizing its goal of being a global biosimilars leader. Tambe takes over from Dr Arun Chandavarkar, who will continue to serve as a non-Executive, non-Independent Director on the Board of Biocon Biologics.Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
